Saguaro Technologies Inc., a Quebec City, Canada-based developer of technologies for drug discovery, closed a $1.1M financing.
The round was led by a biotech investor and included non-dilutive grant funding.
The company intends to use the funds for the full-scale rollout of its technologies.
Led by Louis Turcotte Co-Founder & Chief Executive Officer, and Félix Lavoie-Pérusse, Co-Founder & Chief Commercial Officer, Saguaro provides products for drug developers to make the most of their in vitro models, with the goal of generating new data that is more predictive of results in clinical trials with humans.
FinSMEs
16/02/2022